Zobrazeno 1 - 10
of 321
pro vyhledávání: '"Joshua J Gagne"'
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0227783 (2020)
PurposeTo quantify differences in the age, gender, race, and clinical complexity of Medicare beneficiaries treated by ophthalmologists and optometrists in each of the United States.DesignCross-sectional study based on publicly accessible Medicare pay
Externí odkaz:
https://doaj.org/article/e9ffedb5543744c2ad546a82c4f7fdc5
Autor:
Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John G Connolly, Michael A Fischer, Aaron S Kesselheim, Joshua J Gagne
Publikováno v:
PLoS Medicine, Vol 16, Iss 3, p e1002763 (2019)
BackgroundTo the extent that outcomes are mediated through negative perceptions of generics (the nocebo effect), observational studies comparing brand-name and generic drugs are susceptible to bias favoring the brand-name drugs. We used authorized ge
Externí odkaz:
https://doaj.org/article/51ccf41e807b4815bcd7459a5be71630
Autor:
Alyssa Wohlfahrt, Anarosa Campos, Maura D Iversen, Joshua J Gagne, Elena Massarotti, Daniel H Solomon, Candace H Feldman
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0200886 (2018)
OBJECTIVE:Adherence to medications among patients with rheumatic diseases is often suboptimal. Patient navigators, individuals trained in care coordination, motivational interviewing and basic rheumatology and pharmacology, have not been employed to
Externí odkaz:
https://doaj.org/article/e21ee99208d34c2b9c80862921f9d907
Autor:
Aaron S Kesselheim, Wesley Eddings, Tara Raj, Eric G Campbell, Jessica M Franklin, Kathryn M Ross, Lisa A Fulchino, Jerry Avorn, Joshua J Gagne
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0163339 (2016)
Generic drugs are cost-effective versions of brand-name drugs approved by the Food and Drug Administration (FDA) following proof of pharmaceutical equivalence and bioequivalence. Generic drugs are widely prescribed by physicians, although there is di
Externí odkaz:
https://doaj.org/article/bf8408306e7c4deebf5eb391481ce785
Publikováno v:
JAMA Internal Medicine.
ImportanceClinical guidelines on chronic obstructive pulmonary disease (COPD) recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long-acting β-agonists (LABAs) over inhalers containing inhaled corticosteroids (ICSs) and LAB
Autor:
Nazleen F. Khan, Katsiaryna Bykov, Michael L. Barnett, Robert J. Glynn, Seanna M. Vine, Joshua J. Gagne
Publikováno v:
Neurology. 99:e1432-e1442
Background and ObjectivesThe concomitant use of prescription opioids and skeletal muscle relaxants has been associated with opioid overdose, but little data exist on the head-to-head safety of these drug combinations. The objective of this study was
Autor:
John Tazare, Richard Wyss, Jessica M. Franklin, Liam Smeeth, Stephen J. W. Evans, Shirley V. Wang, Sebastian Schneeweiss, Ian J. Douglas, Joshua J. Gagne, Elizabeth J. Williamson
Publikováno v:
Pharmacoepidemiology and Drug Safety. 31:411-423
The high-dimensional propensity score (HDPS) is a semi-automated procedure for confounder identification, prioritisation and adjustment in large healthcare databases that requires investigators to specify data dimensions, prioritisation strategy and
Publikováno v:
Emerging Themes in Epidemiology, Vol 13, Iss 1, Pp 1-10 (2016)
Abstract Background Multivariable confounder adjustment in comparative studies of newly marketed drugs can be limited by small numbers of exposed patients and even fewer outcomes. Disease risk scores (DRSs) developed in historical comparator drug use
Externí odkaz:
https://doaj.org/article/f5389c689b434ced8cc9feec8da3ffec
Autor:
Joshua J. Gagne, Jerry Avorn, Nicolle M. Gatto, Jingping Mo, Gerald J. Dal Pan, June Raine, Shinobu Uzu, Aaron S. Kesselheim, Kerstin N. Vokinger
Publikováno v:
Textbook of Pharmacoepidemiology. :73-111
Autor:
Kueiyu Joshua Lin, Elvira D'Andrea, Rishi J. Desai, Joshua J. Gagne, Jun Liu, Shirley V. Wang
Publikováno v:
Pharmacoepidemiology and drug safetyREFERENCES.
We sought to develop and prospectively validate a dynamic model that incorporates changes in biomarkers to predict rapid clinical deterioration in patients hospitalized for COVID-19.We established a retrospective cohort of hospitalized patients aged